Zentalis Pharmaceuticals (ZNTL) Capital Expenditures (2019 - 2026)

Zentalis Pharmaceuticals' Capital Expenditures history runs 7 years deep, the most recent figure standing at $34000.0 for Q1 2026.

• On a quarterly basis, Capital Expenditures changed N/A year-over-year to $34000.0 in Q1 2026; TTM through Mar 2026 was $34000.0, a 81.22% decrease from a year earlier, with the FY2024 full-year figure at $221000.0, down 62.09% from the prior year.
• Capital Expenditures eased to $34000.0 in Q1 2026 per ZNTL's latest filing, from $181000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $2.3 million in Q3 2022 and bottomed at -$135000.0 in Q2 2022.
• The 4-year median for Capital Expenditures is $166500.0 (2022), against an average of $338600.0.
• Across the five-year window, Capital Expenditures tumbled 116.48% in 2022 and surged 336.3% in 2023, its largest moves.
• Year by year, Capital Expenditures stood at $160000.0 in 2022, then rose by 8.12% to $173000.0 in 2023, then climbed by 4.62% to $181000.0 in 2024, then sank by 81.22% to $34000.0 in 2026.
• Per Business Quant, the three latest ZNTL Capital Expenditures figures stand at $34000.0 (Q1 2026), $181000.0 (Q2 2024), and $40000.0 (Q1 2024).